Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology
Vaccination programs with the current prophylactic HPV vaccines started in most countries around 2008 with introduction of the bivalent Cervarix HPV16/18 vaccine, rapidly followed by Gardasil (HPV6/11/16/18) and, finally, Gardasil 9 (HPV6/11/16/18/31/33/45/52/58), from 2015. Many studies have now co...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/4/757 |
| _version_ | 1797443262650253312 |
|---|---|
| author | Ian N. Hampson |
| author_facet | Ian N. Hampson |
| author_sort | Ian N. Hampson |
| collection | DOAJ |
| description | Vaccination programs with the current prophylactic HPV vaccines started in most countries around 2008 with introduction of the bivalent Cervarix HPV16/18 vaccine, rapidly followed by Gardasil (HPV6/11/16/18) and, finally, Gardasil 9 (HPV6/11/16/18/31/33/45/52/58), from 2015. Many studies have now confirmed their ability to prevent infection with vaccine-covered HPV types, and the subsequent development of either genital warts and/or cervical neoplasia, although this is clearly more effective in younger women vaccinated prior to sexual debut. Most notably, reductions in the prevalence of vaccine-covered HPV types were also observed in unvaccinated women at the same geographical location, presumably by sexual dissemination of these changes, between vaccinated and unvaccinated women. Furthermore, there are several studies that have demonstrated vaccine-associated HPV type-replacement, where vaccine-covered, high-risk HPV types are replaced by high-risk HPV types not covered by the vaccines, and these changes were also observed in vaccinated and unvaccinated women in the same study population. In light of these observations, it is not entirely clear what effects vaccine-associated HPV type-replacement will have, particularly in older, unvaccinated women. |
| first_indexed | 2024-03-09T12:53:25Z |
| format | Article |
| id | doaj.art-f336b0170bd24fc4ab55d6a542f2e0d5 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T12:53:25Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-f336b0170bd24fc4ab55d6a542f2e0d52023-11-30T22:03:47ZengMDPI AGViruses1999-49152022-04-0114475710.3390/v14040757Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical PathologyIan N. Hampson0Division of Cancer Sciences, University of Manchester, Oxford Rd, Manchester M13 9WL, UKVaccination programs with the current prophylactic HPV vaccines started in most countries around 2008 with introduction of the bivalent Cervarix HPV16/18 vaccine, rapidly followed by Gardasil (HPV6/11/16/18) and, finally, Gardasil 9 (HPV6/11/16/18/31/33/45/52/58), from 2015. Many studies have now confirmed their ability to prevent infection with vaccine-covered HPV types, and the subsequent development of either genital warts and/or cervical neoplasia, although this is clearly more effective in younger women vaccinated prior to sexual debut. Most notably, reductions in the prevalence of vaccine-covered HPV types were also observed in unvaccinated women at the same geographical location, presumably by sexual dissemination of these changes, between vaccinated and unvaccinated women. Furthermore, there are several studies that have demonstrated vaccine-associated HPV type-replacement, where vaccine-covered, high-risk HPV types are replaced by high-risk HPV types not covered by the vaccines, and these changes were also observed in vaccinated and unvaccinated women in the same study population. In light of these observations, it is not entirely clear what effects vaccine-associated HPV type-replacement will have, particularly in older, unvaccinated women.https://www.mdpi.com/1999-4915/14/4/757HPVvaccinesprophylacticcervical cancerHPV type-replacementcervical intraepithelial neoplasia |
| spellingShingle | Ian N. Hampson Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology Viruses HPV vaccines prophylactic cervical cancer HPV type-replacement cervical intraepithelial neoplasia |
| title | Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology |
| title_full | Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology |
| title_fullStr | Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology |
| title_full_unstemmed | Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology |
| title_short | Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology |
| title_sort | effects of the prophylactic hpv vaccines on hpv type prevalence and cervical pathology |
| topic | HPV vaccines prophylactic cervical cancer HPV type-replacement cervical intraepithelial neoplasia |
| url | https://www.mdpi.com/1999-4915/14/4/757 |
| work_keys_str_mv | AT iannhampson effectsoftheprophylactichpvvaccinesonhpvtypeprevalenceandcervicalpathology |